Our research program aims firstly to bring genome sequencing to the bedside by allowing it to guide decisions that impact individual patients affected by these infections, whether by allowing more personalised therapy, by facilitating early detection of infection or by preventing infections through more rapid and effective management of outbreaks. We then aim to use artificial intelligence to inform better predictions in these situations, incorporating both these genomic data and clinical data mined from electronic medical records. These include predicting presence of antibiotic or antiviral resistance, predicting future risks that patients face such as clinical deteriorations or mortality and predicting the likelihood of transmission of these deadly pathogens in hospital settings.